Nutriband Inc. Pioneers Abuse-Deterrent Technology for Fentanyl Delivery

Nutriband Inc. (NASDAQ: NTRB) is making strides in the development of Aversa(TM), a proprietary abuse-deterrent transdermal technology aimed at preventing the diversion, misuse, abuse, and accidental exposure of potent opioids such as fentanyl. With fentanyl being approximately 50 times more potent than heroin, the development of safe and effective delivery systems is crucial. Nutriband's innovative approach could significantly impact the healthcare industry by offering a solution that balances patient access with the need to mitigate misuse.

The Aversa(TM) fentanyl patch, developed by Nutriband, is estimated to have an annual market potential ranging from $80 million to $200 million within five years of its launch. This projection underscores the importance of Nutriband's work in addressing a pressing public health issue. The company's efforts are particularly relevant given the high stakes associated with fentanyl, where even trace amounts can be fatal, highlighting the need for technologies that can prevent its misuse.

For more information on Nutriband's developments and updates, interested parties can visit the company's newsroom at https://ibn.fm/NTRB. Nutriband's commitment to pioneering transdermal technologies for controlled substances places it at the forefront of a critical area in modern healthcare, offering potential solutions to some of the most challenging aspects of drug delivery today.